FDA clears QIAstat-Dx bloodstream infection panel
Aug. 11, 2026—The FDA has cleared Qiagen’s QIAstat-Dx BCID GPF Plus AMR panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Proscia gets new clearance for Concentriq AP-Dx
Aug. 10, 2026—Proscia received a new FDA 510(k) clearance for the Concentriq AP-Dx, a digital pathology platform for primary diagnosis.
Roche expands cyclospora testing portfolio in U.S.
Aug. 7, 2026—Roche, in collaboration with subsidiary Tib Molbiol, released two research PCR testing options for labs to address the public health impact of the Cyclospora cayetanensis parasite.
Epredia adds BlockTracker, SlideTracker to portfolio
Aug. 6, 2026—Epredia announced an agreement with Canada-based manufacturer Lab Improvements to bring automated archiving to U.S. pathology labs, adding Lab Improvements’ BlockTracker and SlideTracker to its product portfolio.
Roche gets FDA clearance for Cobas BV/CV assay
July 29, 2026–Roche received FDA 510(k) clearance for its Cobas BV/CV assay.
Beckman Coulter launches DxU 1800 automated urinalysis solution
July 29, 2026—Beckman Coulter Diagnostics has launched in the U.S. its DxU 1800 system, a fully automated urinalysis solution that combines the new DxU 1800c chemistry analyzer with a DxU Iris microscopy analyzer.
Waters launches Xevo TQ Absolute XR IVD mass spectrometer
July 28, 2026—Waters Corp. launched the Xevo TQ Absolute XR IVD mass spectrometer, expanding its MassTrak IVD system portfolio of LC-MS/MS systems.
Hardy Diagnostics showcases rapid lateral flow assays to combat AMR
July 28, 2026—Antimicrobial resistance (AMR) remains one of the most significant challenges facing health care today.
Werfen hosts education event on anticoagulation management
July 28, 2026—Werfen is hosting an education event on Wednesday, July 29, titled “Leading Change in Anticoagulation Management: Anti-Xa for Unfractionated Heparin Monitoring Across Lab, Pharmacy and Clinical Teams.”
ZeptoMetrix molecular quality controls on NATtrol swabs
July 28, 2026—Beyond our traditional liquid format, ZeptoMetrix introduces molecular quality controls on swabs.